MAST Biosurgery

Executive Summary

MAST Biosurgery is a San Diego-based medical device company specializing in bioresorbable polymer implants for soft tissue repair and reconstruction. Founded in 2003, the company has developed a proprietary technology platform that provides temporary structural support during healing and then safely resorbs, reducing long-term complications associated with permanent implants. Their product portfolio includes absorbable surgical meshes and tissue regeneration products targeting various surgical specialties such as hernia repair, pelvic floor reconstruction, and plastic surgery. By focusing on bioresorbable solutions, MAST addresses a significant unmet need for safer, biocompatible implants that minimize foreign body reactions and chronic pain. As a private company with a long track record, MAST is well-positioned to capitalize on the growing demand for advanced wound care and regenerative medicine products. The global surgical mesh market is expanding, driven by increasing surgical volumes and preference for minimally invasive procedures. MAST's differentiation lies in its material science expertise and regulatory experience, having gained FDA clearances for multiple products. However, the company faces competition from established players like Johnson & Johnson and Medtronic, as well as emerging startups. To drive growth, MAST may pursue new product launches, geographic expansion, or strategic partnerships. Its focus on bioresorbable technology aligns with industry trends toward reducing permanent implant burden, suggesting steady revenue growth potential.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation hernia mesh70% success
• Q4 2026Strategic partnership with a major surgical device distributor60% success
• Q1 2027Positive 2-year clinical data for pelvic floor repair implant75% success